Significant loss of efficacy vs B1.617 Indian sarscov2variant

alpha

visibility 508

Health

5/1/2021


0 likes


It is very likely that B.1.617 that ravaged India now has already spread globally. B1617 has E484Q mutation which as expected causes a 6 fold loss in efficacy vs Pfizer vaccine induced immunity in studies bringing Pfizer efficacy vs B1617 to just 15-23%. The second mutation, L452 has a 4 fold loss.

Comment